Furthermore, elevated TGF-β levels contribute to drug resistance by modulating the immune response, promoting tumor vascularization and reducing the effectiveness of both antiangiogenic therapies and immune checkpoint inhibitors [61]. Here, TGFB1 is linked to neoplasm.